Quantcast

Latest Piperazines Stories

2014-09-09 08:32:06

For U.S. Media Only RIDGEFIELD, Conn., Sept. 9, 2014 /PRNewswire/ -- A pre-specified, pooled subgroup sensitivity analysis from the two identically designed Phase III INPULSIS(TM) trials, presented today at the European Respiratory Society International Congress (ERS) evaluated the impact of the investigational drug nintedanib on reducing the decline in lung function, as measured by annual rate of decline in forced vital capacity (FVC), in patients with idiopathic pulmonary fibrosis (IPF)...

2014-09-03 23:09:16

LifeScienceIndustryResearch.com adds Latest Report on “Market Research Report on Global and Chinese Ciprofloxacin HCl Industry, 2009-2019” to its store. Inquire Before Buying on this report at http://www.lifescienceindustryresearch.com/inquire-before-buying?rname=9568 Dallas, TX (PRWEB) September 03, 2014 Market Research Report on Global and Chinese Ciprofloxacin HCl Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Ciprofloxacin HCl industry. The...

2014-08-25 23:00:16

New Study Finding Supports Allegations in over 700 Risperdal Lawsuits of the Development of Male Breast Enlargement after Taking Risperdal, Reports Wright & Schulte LLC Columbus, OH (PRWEB) August 26, 2014 A recently released study supports claims in Risperdal lawsuits that the antipsychotic drug Risperdal can cause the develop gynecomastia, or abnormal breast growth. In the study published on August 6, 2014, in the Journal of Clinical Psychopharmacology, researchers from the...

2014-08-19 23:02:22

The Firm is representing men and boys in Risperdal lawsuits who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication. New York, New York (PRWEB) August 19, 2014 As Risperdal lawsuits (http://www.risperdallawsuitcenter.com) mount in U.S. courts, Bernstein Liebhard LLP notes the publication of a new study that suggests the use of atypical antipsychotic medications may increase the risk of acute kidney injury in elderly patients....

2014-08-14 12:27:26

Ameritox's Ingenuity Health introduces method to help assess medication adherence in patients prescribed Seroquel XR BALTIMORE, Aug. 14, 2014 /PRNewswire/ -- Ameritox(SM), the nation's leader in medication monitoring solutions, today launched a method to help assess medication adherence in behavioral health patients prescribed the antipsychotic drug Seroquel XR, one of the 40 best-selling medications in the U.S. This new method marks a critical step toward building a comprehensive...

2014-08-11 08:28:42

LONDON, August 11, 2014 /PRNewswire/ -- Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF(R) (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July...

2014-08-09 23:03:20

Risperdal Lawsuit Claims Continue to Be Filed Against Johnson & Johnson Contending Male Breast Growth Due to the Manufacturer’s Antipsychotic Drug Risperdal Reports Wright & Schulte LLC Columbus, OH (PRWEB) August 09, 2014 Risperdal lawsuits currently pending litigation in the Philadelphia Court of Common Pleas in Pennsylvania have grown to 662 Risperdal lawsuit claims filed against the makers of the antipsychotic drug, notes Wright & Schulte LLC. According to the court...

2014-08-08 08:26:35

First ADASUVE Launch in Latin America MOUNTAIN VIEW, Calif., Aug. 8, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE(®) inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. Ferrer is Alexza's commercial partner for ADASUVE in the EU, Latin America and Commonwealth of Independent States countries. Ferrer introduced ADASUVE during a...

2014-08-05 08:33:13

Peer-Reviewed Case Study from Fox Chase Cancer Center Demonstrates Value of Company's Unique Approach to Precision Medicine to Uncover Critical Treatment Insights IRVING, Texas, Aug. 5, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today publication of a case study in which the company's comprehensive tumor profiling service, Caris Molecular Intelligence(TM), helped guide successful...

2014-07-30 12:30:25

PISCATAWAY, N.J., July 30, 2014 /PRNewswire/ -- InnoPharma, Inc. today announced the first generic launch of Olanzapine for Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada. Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania. As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related